{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:41:20Z","timestamp":1793209280726,"version":"4.5.0"},"reference-count":216,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.drup.2026.101383","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:19:58Z","timestamp":1772036398000},"page":"101383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7017-8213","authenticated-orcid":false,"given":"Sieun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6902-7804","authenticated-orcid":false,"given":"Jihye","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Yeon","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5481-2202","authenticated-orcid":false,"given":"Jihye","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4479-9374","authenticated-orcid":false,"given":"Inah","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101383_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat. Med"},{"key":"10.1016\/j.drup.2026.101383_bib2","article-title":"and C.L.L.T. Investigators. Fixed-duration versus continuous treatment for chronic lymphocytic leukemia","author":"Al-Sawaf","year":"2025","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101383_bib3","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2021.280061","article-title":"Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies","volume":"107","author":"Allan","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2026.101383_bib4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3324\/haematol.2021.279158","article-title":"Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase","volume":"107","author":"Aslan","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2026.101383_bib6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-022-00675-9","article-title":"Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia","volume":"12","author":"Aslan","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drup.2026.101383_bib7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/JLB.MR0318-096R","article-title":"Understanding early TLR signaling through the Myddosome","volume":"105","author":"Balka","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.drup.2026.101383_bib8","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1474-4422(25)00174-7","article-title":"Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study","volume":"24","author":"Bar-Or","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drup.2026.101383_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drup.2026.101383_bib11","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jaci.2023.12.008","article-title":"BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria","volume":"153","author":"Bernstein","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.drup.2026.101383_bib12","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41375-025-02662-y","article-title":"Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice","volume":"39","author":"Blombery","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2026.101383_bib13","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2026.101383_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.74","article-title":"Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients","volume":"5","author":"Boissard","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drup.2026.101383_bib15","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2026.101383_bib17","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.drup.2026.101383_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101383_bib19","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101383_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study","volume":"40","author":"Buske","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101383_bib22","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7083","article-title":"A phase I, first-in-human study of ONO-7018 in patients with relapsed\/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia","author":"Byrd","year":"2024","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib24","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.18632\/oncotarget.24310","article-title":"First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL","volume":"9","author":"Byrd","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.drup.2026.101383_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/PO.20.00360","article-title":"Acquired CARD11 mutation promotes BCR independence in Diffuse Large B Cell Lymphoma","author":"Caeser","year":"2021","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2026.101383_bib27","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood.2023022993","article-title":"Degraders upgraded: the rise of PROTACs in hematological malignancies","volume":"143","author":"Casan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib28","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2026.101383_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/ar3400","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells","volume":"13","author":"Chang","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.drup.2026.101383_bib30","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","volume":"29","author":"Cheng","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2026.101383_bib31","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1073\/pnas.1921187117","article-title":"Regulation of B cell receptor-dependent NF-kappaB signaling by the tumor suppressor KLHL14","volume":"117","author":"Choi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101383_bib32","article-title":"A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed\/refractory B-cell malignancies","author":"Chong","year":"2024","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/1074-7613(95)90155-8","article-title":"Cytotoxic antibodies trigger inflammation through Fc receptors","volume":"3","author":"Clynes","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2026.101383_bib34","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2023-181627","article-title":"Pirtobrutinib in relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) patients with prior cBTKi: safety and efficacy including high-risk subgroup analyses from the phase 1\/2 BRUIN study","volume":"142","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-025-01214-y","article-title":"Bruton's tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax","volume":"15","author":"Coughlin","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drup.2026.101383_bib36","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2023-179872","article-title":"A first-in-Human phase 1 trial of NX-2127, a first-in-class Bruton's Tyrosine Kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with relapsed\/refractory B cell malignancies","volume":"142","author":"Danilov","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib37","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/blood-2021-146348","article-title":"Final results of a phase 1\/2 study of SYK inhibitor entospletinib in combination with obinutuzumab in patients with Relapsed\/Refractory (R\/R) chronic lymphocytic leukemia (CLL)","volume":"138","author":"Danilov","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib38","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.drup.2026.101383_bib39","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1182\/bloodadvances.2020002810","article-title":"Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy","volume":"4","author":"Davis","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2026.101383_bib40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101383_bib41","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101383_bib42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing","volume":"26","author":"de Gorter","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2026.101383_bib43","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3324\/haematol.2019.227272","article-title":"MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications","volume":"104","author":"de Groen","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2026.101383_bib44","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1002\/eji.1830231210","article-title":"The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages","volume":"23","author":"de Weers","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.drup.2026.101383_bib45","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1182\/blood.2023020211","article-title":"CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma","volume":"142","author":"Decombis","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib46","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1158\/1078-0432.CCR-24-0028","article-title":"A Phase 1 first-in-human study of the MCL-1 inhibitor AZD5991 in patients with relapsed\/refractory hematologic malignancies","volume":"30","author":"Desai","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101383_bib47","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101383_bib48","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib49","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1172\/JCI138448","article-title":"Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis","volume":"130","author":"Dispenza","year":"2020","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.drup.2026.101383_bib50","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.2147\/DDDT.S377697","article-title":"Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical","volume":"16","author":"Dong","year":"2022","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.drup.2026.101383_bib51","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1182\/blood-2014-05-574830","article-title":"PKC-beta as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL","volume":"124","author":"El-Gamal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib52","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/bloodadvances.2018029058","article-title":"Resistance mechanism for ibrutinib in marginal zone lymphoma","volume":"3","author":"Epperla","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2026.101383_bib53","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","article-title":"BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib","volume":"35","author":"Estupinan","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2026.101383_bib54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1074-7613(00)80591-9","article-title":"BLNK: a central linker protein in B cell activation","volume":"9","author":"Fu","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2026.101383_bib55","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2019.10.033","article-title":"Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer","volume":"139","author":"Gerber","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.drup.2026.101383_bib56","doi-asserted-by":"crossref","first-page":"8878","DOI":"10.1016\/S0021-9258(17)37050-3","article-title":"Physical and functional association of Src-related protein tyrosine kinases with Fc gamma RII in monocytic THP-1 cells","volume":"269","author":"Ghazizadeh","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2026.101383_bib57","article-title":"Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies","author":"Gimenez-Arnau","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.drup.2026.101383_bib58","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1182\/blood-2023-181151","article-title":"A phase 1a\/b trial of luxeptinib (CG-806) in patients with relapsed\/refractory B-cell malignancies or acute myeloid leukemia and evaluation of new G3 formulation","volume":"142","author":"Goldberg","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib59","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib60","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2023-189746","article-title":"Takeaim lymphoma: an open-label, dose escalation and expansion trial of emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed or refractory hematologic Malignancies","volume":"142","author":"Grommes","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib61","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/1535-7163.MCT-17-0784","article-title":"p110alpha Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma","volume":"17","author":"Guan","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101383_bib62","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies","volume":"36","author":"Guieze","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101383_bib63","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.18632\/oncotarget.14588","article-title":"Dual SYK\/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101383_bib64","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-kappaB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.drup.2026.101383_bib65","doi-asserted-by":"crossref","first-page":"E90","DOI":"10.1002\/ajh.25387","article-title":"Efficacy and safety of the dual SYK\/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study","volume":"94","author":"Hamlin","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drup.2026.101383_bib66","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.2023023388","article-title":"Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions","volume":"144","author":"Handunnetti","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib67","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/s41418-020-00692-w","article-title":"Regulation of Bcl-XL by non-canonical NF-kappaB in the context of CD40-induced drug resistance in CLL","volume":"28","author":"Haselager","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.drup.2026.101383_bib68","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-18450-8","article-title":"Expanded CD16(+)CD56(+)Granzyme B(+) NK like CD8(+) T cells an off target effect of bruton's tyrosine kinase inhibitors in Waldenstrom macroglobulinemia","volume":"15","author":"Hastak","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101383_bib70","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1084\/jem.187.8.1235","article-title":"Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production","volume":"187","author":"Hata","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2026.101383_bib71","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101383_bib72","article-title":"Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma","volume":"5","author":"Hoang","year":"2024","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.drup.2026.101383_bib73","article-title":"Leveraging BRG1 driven ferroptosis resistance to overcome treatment resistance","author":"Hwang","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.drup.2026.101383_bib74","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41408-023-00927-2","article-title":"Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma","volume":"13","author":"Jain","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drup.2026.101383_bib75","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165694","article-title":"Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma","volume":"133","author":"Jiang","year":"2023","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.drup.2026.101383_bib76","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/bjh.16463","article-title":"Genomic evolution of ibrutinib-resistant clones in Waldenstrom macroglobulinaemia","volume":"189","author":"Jimenez","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2026.101383_bib77","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.95488","article-title":"Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia","volume":"13","author":"Joseph","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.drup.2026.101383_bib78","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164573","article-title":"A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma","volume":"135","author":"Kang","year":"2025","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.drup.2026.101383_bib79","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41419-019-2158-0","article-title":"Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies","volume":"10","author":"Kapoor","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101383_bib80","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1084\/jem.20151074","article-title":"Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy","volume":"212","author":"Kelly","year":"2015","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.drup.2026.101383_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074103","article-title":"Bruton's tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin","volume":"8","author":"Kenny","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2026.101383_bib82","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1385\/IR:23:2-3:147","article-title":"Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase","volume":"23","author":"Khan","year":"2001","journal-title":"Immunol. Res."},{"key":"10.1016\/j.drup.2026.101383_bib83","doi-asserted-by":"crossref","first-page":"24442","DOI":"10.1016\/S0021-9258(20)80545-6","article-title":"Cross-linking of Fc gamma receptor I (Fc gamma RI) and receptor II (Fc gamma RII) on monocytic cells activates a signal transduction pathway common to both Fc receptors that involves the stimulation of p72 Syk protein tyrosine kinase","volume":"268","author":"Kiener","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2026.101383_bib84","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2011-12-397919","article-title":"Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice","volume":"119","author":"Kil","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib85","doi-asserted-by":"crossref","first-page":"9986","DOI":"10.1128\/MCB.24.22.9986-9999.2004","article-title":"Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2","volume":"24","author":"Kim","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.drup.2026.101383_bib86","doi-asserted-by":"crossref","first-page":"E7230","DOI":"10.1073\/pnas.1507459112","article-title":"Lymphomagenic CARD11\/BCL10\/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-kappaB and JNK activation","volume":"112","author":"Knies","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101383_bib87","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kramer","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.drup.2026.101383_bib88","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood.2024027336","article-title":"Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study","volume":"145","author":"Kuter","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib89","article-title":"Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia","volume":"6","author":"Kutsch","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.drup.2026.101383_bib90","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","article-title":"Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease","volume":"206","author":"Langrish","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.drup.2026.101383_bib91","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101383_bib92","first-page":"206","article-title":"Efficacy\/Safety of the BTK Degrader NX-5948 in Waldenstr\u00f6m macroglobulinemia: An Ongoing Phase 1a\/b Study","author":"Lewis","year":"2025","journal-title":"Brit J. Haematol."},{"key":"10.1016\/j.drup.2026.101383_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11080764","article-title":"Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies","volume":"11","author":"Lewis","year":"2021","journal-title":"J. Pers. Med"},{"key":"10.1016\/j.drup.2026.101383_bib94","article-title":"Phase 1\/2 studies of DZD8586 in CLL\/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders","author":"Li","year":"2025","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib95","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3324\/haematol.2022.281538","article-title":"Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma","volume":"108","author":"Li","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2026.101383_bib96","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41419-023-06233-w","article-title":"Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101383_bib97","article-title":"Recall of ibrutinib and issues with therapeutic approval","volume":"3","author":"Lipfert","year":"2024","journal-title":"BMJ Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib98","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-017-0512-1","article-title":"Syk inhibitors in clinical development for hematological malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib99","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib100","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ni.2015","article-title":"Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk","volume":"12","author":"Liu","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drup.2026.101383_bib101","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.2023020142","article-title":"EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma","volume":"142","author":"Liu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib102","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3324\/haematol.2022.282031","article-title":"Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma","volume":"108","author":"Liu","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2026.101383_bib103","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.drup.2026.101383_bib104","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1074\/jbc.M110390200","article-title":"G Protein beta gamma subunits act on the catalytic domain to stimulate Bruton's agammaglobulinemia tyrosine kinase","volume":"277","author":"Lowry","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2026.101383_bib105","doi-asserted-by":"crossref","first-page":"43881","DOI":"10.18632\/oncotarget.6316","article-title":"Cerdulatinib, a novel dual SYK\/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma","volume":"6","author":"Ma","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101383_bib106","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib107","first-page":"6","article-title":"The Tec family protein-tyrosine kinases: a subset of kinases for a subset of signalings","volume":"69","author":"Mano","year":"1999","journal-title":"Int J. Hematol."},{"key":"10.1016\/j.drup.2026.101383_bib108","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2011.10.009","article-title":"Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines","volume":"129","author":"Marron","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.drup.2026.101383_bib109","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2026.101383_bib110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101383_bib111","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria","volume":"150","author":"Maurer","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.drup.2026.101383_bib112","first-page":"2077","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"Reply. N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101383_bib113","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib114","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ajh.27544","article-title":"Prevalence of BTK and PLCG2 Mutations in CLL Patients With Disease Progression on BTK Inhibitor Therapy: A Meta-Analysis","volume":"100","author":"Molica","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drup.2026.101383_bib115","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101383_bib116","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13045-022-01386-1","article-title":"Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia","volume":"15","author":"Muhowski","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib117","first-page":"206","article-title":"Efficacy\/Safety of the BTK Degrader NX-5948 in Chronic Lymphocytic Leukemia: An Ongoing Phase 1a\/b Study","author":"Munir","year":"2025","journal-title":"Brit J. Haematol."},{"key":"10.1016\/j.drup.2026.101383_bib118","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2026.101383_bib119","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101383_bib120","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1182\/blood-2008-08-174110","article-title":"The NF-kappaB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas","volume":"113","author":"Novak","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib121","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1182\/blood-2024-208359","article-title":"Preliminary safety and efficacy of emavusertib (CA-4948) in combination with ibrutinib in relapsed\/refractory primary central nervous system lymphoma patients with prior exposure to BTK inhibitor","volume":"144","author":"Nowakowski","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib122","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib123","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S1074-7613(00)80568-3","article-title":"CD19 as a membrane-anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav","volume":"8","author":"O'Rourke","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2026.101383_bib124","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/blood-2023-182838","article-title":"A Phase 1, open-label, multicenter, dose-escalation study of Sgr-1505 as monotherapy in subjects with mature B-cell malignancies","volume":"142","author":"Olszewski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib125","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173770","article-title":"FoxO1\/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia","volume":"134","author":"Ondrisova","year":"2024","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.drup.2026.101383_bib126","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","article-title":"Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study","volume":"7","author":"Opat","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2026.101383_bib127","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101383_bib128","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-7003","article-title":"NX-5948 is a CNS-penetrant catalytic Bruton's tyrosine kinase (BTK) degrader that breaks established design rules for CNS drugs","volume":"85","author":"Palmer","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101383_bib129","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1038\/s41375-019-0463-3","article-title":"CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages","volume":"33","author":"Papin","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2026.101383_bib130","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1159\/000537791","article-title":"Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature","volume":"147","author":"Parigger","year":"2024","journal-title":"Acta Haematol."},{"key":"10.1016\/j.drup.2026.101383_bib131","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2023.12.019","article-title":"Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy","volume":"42","author":"Phelan","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101383_bib132","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","article-title":"A multiprotein supercomplex controlling oncogenic signalling in lymphoma","volume":"560","author":"Phelan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101383_bib133","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in Relapsed\/Refractory Mantle Cell Lymphoma: Results From a Phase I\/II Study","volume":"43","author":"Phillips","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib134","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-18-3275","article-title":"Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma","volume":"25","author":"Prukova","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2026.101383_bib135","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1182\/bloodadvances.2021006555","article-title":"A phase 1 trial of copanlisib plus ibrutinib in relapsed\/refractory mantle cell lymphoma","volume":"6","author":"Qualls","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2026.101383_bib136","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41408-021-00520-5","article-title":"Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression","volume":"11","author":"Quijada-Alamo","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drup.2026.101383_bib137","first-page":"89","article-title":"Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenstrom's Macroglobulinemia","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.drup.2026.101383_bib138","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat. Med"},{"key":"10.1016\/j.drup.2026.101383_bib139","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101383_bib140","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2017-10-809020","article-title":"Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL","volume":"132","author":"Reiff","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib141","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","article-title":"Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies","volume":"67","author":"Robbins","year":"2024","journal-title":"J. Med Chem."},{"key":"10.1016\/j.drup.2026.101383_bib142","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1097-2765(02)00739-6","article-title":"Amplification of B cell antigen receptor signaling by a Syk\/ITAM positive feedback loop","volume":"10","author":"Rolli","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.drup.2026.101383_bib143","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3324\/haematol.2017.177162","article-title":"Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment","volume":"103","author":"Rudelius","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2026.101383_bib144","doi-asserted-by":"crossref","first-page":"7038","DOI":"10.1158\/0008-5472.CAN-17-2485","article-title":"MALT1 Inhibition Is Efficacious in Both Naive and Ibrutinib-Resistant Chronic Lymphocytic Leukemia","volume":"77","author":"Saba","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101383_bib145","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17030557","article-title":"BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL","volume":"17","author":"Salvaris","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2026.101383_bib146","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1182\/blood-2023-179508","article-title":"Initial findings from a first-in-human phase 1a\/b trial of NX-5948, a selective Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed\/refractory B cell malignancies","volume":"142","author":"Searle","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib147","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/cas.15344","article-title":"Two-year outcomes of tirabrutinib monotherapy in Waldenstrom's macroglobulinemia","volume":"113","author":"Sekiguchi","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2026.101383_bib148","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2023-180109","article-title":"First results from a phase 1, first-in-human study of the Bruton's tyrosine kinase (BTK) degrader Bgb-16673 in patients (Pts) with relapsed or refractory (R\/R) B-cell malignancies (BGB-16673-101)","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib149","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1200\/JCO-25-00758","article-title":"Zanubrutinib and Venetoclax for Patients With Treatment-Naive Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma With and Without Del(17p)\/TP53 Mutation: SEQUOIA Arm D Results","volume":"43","author":"Shadman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib150","first-page":"92","article-title":"Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I\/II BRUIN trial","volume":"110","author":"Shah","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2026.101383_bib151","doi-asserted-by":"crossref","first-page":"68833","DOI":"10.18632\/oncotarget.11932","article-title":"Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL","volume":"7","author":"Sharma","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101383_bib152","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00280-016-3010-1","article-title":"A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors","volume":"77","author":"Shimizu","year":"2016","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.drup.2026.101383_bib153","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101383_bib154","unstructured":"H.S.Ao Singapore. Hibruka (orelabrutinib) summary report of benefit-risk assessment. (2022)."},{"key":"10.1016\/j.drup.2026.101383_bib155","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood-2023-181671","article-title":"A first-in-human phase 1 study of ABBV-525, a small-molecule MALT1 inhibitor, in patients with relapsed or refractory B-Cell non-Hodgkin Lymphoma","volume":"142","author":"Sochacki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib156","first-page":"2165","article-title":"Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors","volume":"109","author":"Song","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2026.101383_bib157","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib158","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277003","article-title":"Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma","volume":"18","author":"Sonowal","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2026.101383_bib159","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1078-0432.CCR-21-2183","article-title":"Phase I\/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring","volume":"28","author":"Stewart","year":"2022","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2026.101383_bib161","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri.2017.52","article-title":"The non-canonical NF-kappaB pathway in immunity and inflammation","volume":"17","author":"Sun","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101383_bib162","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jare.2024.08.023","article-title":"Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance","volume":"73","author":"Sun","year":"2025","journal-title":"J. Adv. Res"},{"key":"10.1016\/j.drup.2026.101383_bib163","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-198731","article-title":"Nemtabrutinib versus ibrutinib or acalabrutinib for untreated chronic lymphocytic leukemia\/small lymphocytic lymphoma: the phase 3, open-label, randomized Bellwave-011 study","volume":"144","author":"Tadmor","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib164","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101383_bib165","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1182\/blood-2024-199154","article-title":"Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R\/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study","volume":"144","author":"Tam","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib166","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib167","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s42358-024-00401-y","article-title":"Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments","volume":"64","author":"Tavakoli","year":"2024","journal-title":"Adv. Rheuma"},{"key":"10.1016\/j.drup.2026.101383_bib168","doi-asserted-by":"crossref","first-page":"44221","DOI":"10.1182\/blood-2024-194009","article-title":"A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies","volume":"144","author":"Tees","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib169","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70009","article-title":"CRBN-PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications","volume":"104","author":"Thapa","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.drup.2026.101383_bib170","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41419-022-04684-1","article-title":"Dual BTK\/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma","volume":"13","author":"Thieme","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101383_bib171","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2024-199116","article-title":"Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100034","article-title":"Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice","volume":"1","author":"Timofeeva","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.drup.2026.101383_bib173","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2021-144706","article-title":"Preliminary clinical response data from a phase 1b study of mavorixafor in combination with ibrutinib in patients with waldenstr\u00f6m's macroglobulinemia with MYD88 and CXCR4 mutations","volume":"138","author":"Treon","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib174","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib175","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib176","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood.2021012953","article-title":"Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstrom macroglobulinemia","volume":"138","author":"Treon","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib177","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101383_bib178","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/intimm\/5.7.699","article-title":"The CR2\/CD19 complex on human B cells contains the src-family kinase Lyn","volume":"5","author":"van Noesel","year":"1993","journal-title":"Int Immunol."},{"key":"10.1016\/j.drup.2026.101383_bib179","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.3324\/haematol.2017.168930","article-title":"The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-kappaB mutational status","volume":"102","author":"Vidal-Crespo","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2026.101383_bib180","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44039-0","article-title":"Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia","volume":"13","author":"Vitale","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101383_bib181","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1007\/s00277-023-05314-2","article-title":"Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group","volume":"102","author":"von Tresckow","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.drup.2026.101383_bib182","doi-asserted-by":"crossref","first-page":"22136","DOI":"10.1074\/jbc.M116.746842","article-title":"The Phospholipase Cgamma2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein","volume":"291","author":"Walliser","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2026.101383_bib183","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1084\/jem.180.3.1165","article-title":"Physical and functional association of the high affinity immunoglobulin G receptor (Fc gamma RI) with the kinases Hck and Lyn","volume":"180","author":"Wang","year":"1994","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.drup.2026.101383_bib184","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101383_bib185","article-title":"Zanubrutinib (Zanu) Overcomes BTK-V416L Resistance in B Cell Lymphoma Models","volume":"85","author":"Wang","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101383_bib186","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib187","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101383_bib188","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101383_bib189","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib190","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100001","article-title":"Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers","volume":"1","author":"Wang","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.drup.2026.101383_bib191","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101383_bib192","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1182\/blood.2024026919","article-title":"TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib193","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41375-024-02317-4","article-title":"Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia","volume":"38","author":"Wong","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2026.101383_bib194","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3324\/haematol.2024.285151","article-title":"Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies","volume":"109","author":"Woolston","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2026.101383_bib195","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000969416.78092.36","article-title":"P628: updated analysis of bellwave-001: a phase 1\/2 open-label dose-expansion study of the efficacy and safety of nemtabrutinib for the treatment of b-cell malignancies","volume":"7","author":"Woyach","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.drup.2026.101383_bib196","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101383_bib197","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood.2023023659","article-title":"Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib198","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib199","doi-asserted-by":"crossref","first-page":"38180","DOI":"10.18632\/oncotarget.9500","article-title":"Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101383_bib200","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s10637-022-01219-5","article-title":"Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study","volume":"40","author":"Wu","year":"2022","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.drup.2026.101383_bib201","first-page":"1922","article-title":"BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL","volume":"12","author":"Xia","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101383_bib202","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib203","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.26826","article-title":"Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study","volume":"98","author":"Xu","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drup.2026.101383_bib204","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib205","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2023-172899","article-title":"Discovery of novel, first-in-class allosteric modulators of MALT1 scaffolding function with differentiated pharmacology for NF\u03baB-Driven malignancies","volume":"142","author":"Yao","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101383_bib206","article-title":"Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia","volume":"12","author":"Yi","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib207","article-title":"Three-year follow-up analysis of phase 1\/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma","volume":"6","author":"Yonezawa","year":"2024","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.drup.2026.101383_bib208","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drup.2026.101383_bib209","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-18-0215","article-title":"MYD88 L265P Mutation in Lymphoid Malignancies","volume":"78","author":"Yu","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101383_bib210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102555","article-title":"BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma","volume":"298","author":"Yuan","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2026.101383_bib211","unstructured":"H. Zhang, A. Local, K. Benbatoul, P. Folger, S. Sheng, C.-Y. Tsai, S. Howell and W. Rice. CG'806, a first-in-class non-covalent pan-FLT3\/BTK inhibitor, exerts superior potency against B-cell malignant cells. American Society of Hematology Washington, DC (2017)."},{"key":"10.1016\/j.drup.2026.101383_bib212","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.drup.2026.101383_bib213","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.4049\/jimmunol.1801327","article-title":"Cutting Edge: ROR1\/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway","volume":"203","author":"Zhang","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.drup.2026.101383_bib214","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101383_bib215","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3165_655","article-title":"Treatment OF B-cell malignancies with DZD8586 through overcoming both BTK-dependent and BTK-independent resistance","volume":"41","author":"Zhou","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101383_bib216","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: A Phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:27:49Z","timestamp":1781825269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626000348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":216,"alternative-id":["S1368764626000348"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101383","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101383"}}